Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients
CompletedPhase 3NCT02375633
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients.
Study details
- Conditions
- Interventions
- Drug: DW-330SR2
- Drug: Pelubiprofen
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Start date
- 2014-04
- Primary completion
- 2014-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * More than 12 weeks by the time the trial started , and low back pain that requires analgesia administration. * Class 1 or 2 back pain patients along Quebec Task Force Classification * Patients with pain at least 40mm test results at visit2 * The voluntary or legal guardian 's written consent to participate in this clinical trial subjects Exclusion Criteria: * Severe gastrointestinal disease, heart disease, high blood pressure patients * Patients with secondary causes are obvious * Within 24 weeks patient who has back surgery before clinical trial participation * Within 4 weeks patient who experienced psychotropic drugs, a narcotic analgesic dosage that may affect the pain sensation * Within 4 weeks patient who treated steroid drug by oral or injection * Within 2 weeks patient who treated MAO inhibition drugs * Patients with severe respiratory depression status
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02375633